Garden State Investment Advisory Services LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Garden State Investment Advisory Services LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 3rd quarter, Holdings Channel.com reports. The firm purchased 16,936 shares of the biotechnology company’s stock, valued at approximately $2,115,000.

Other institutional investors also recently bought and sold shares of the company. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth about $31,000. Nkcfo LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth about $43,000. Sunbelt Securities Inc. grew its holdings in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares in the last quarter. Huntington National Bank raised its position in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the last quarter. Finally, Riggs Asset Managment Co. Inc. lifted its stake in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on SRPT shares. UBS Group lifted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI reduced their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Robert W. Baird cut their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price target for the company. Finally, Raymond James reiterated an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

SRPT traded down $1.43 during midday trading on Friday, reaching $123.04. The company’s stock had a trading volume of 64,590 shares, compared to its average volume of 1,220,902. The stock has a market cap of $11.75 billion, a P/E ratio of 99.58 and a beta of 0.77. Sarepta Therapeutics, Inc. has a twelve month low of $89.92 and a twelve month high of $173.25. The company has a fifty day simple moving average of $123.05 and a 200 day simple moving average of $131.30. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.